Onyx Biotec Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Operating margins have improved to 16.7% from 13.1%
- Company maintains a comfortable, low leverage position
CONS
- Receivables are growing faster than sales - a possible quality concern
- Company has a low return on capital employed of 11.6%
- Equity base is being diluted - shares outstanding up 207.2%
- Working capital days have increased from 48 to 138 days
- Debtor days have increased from 69 to 105
- Inventory has been piling up - inventory days up from 52 to 74
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1881.10 | 37.31 | 451338.90 | 0.85 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9570.55 | 86.86 | 254068.03 | 0.31 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4962.75 | 86.55 | 188767.06 | 0.77 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1150.00 | 25.42 | 114712.94 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1383.95 | 33.17 | 111803.57 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1945.50 | 96.14 | 105117.74 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| AUROPHARMA | 1686.00 | 26.13 | 97008.71 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2112.00 | 17.47 | 96574.55 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1151.50 | 29.83 | 96113.39 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2305.85 | 46.63 | 95242.00 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2477.35 | 38.89 | 69916.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| ONYX | 37.55 | 0.00 | 68.09 | 0.00 | — | — | — | — | 13.68 | — |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
No standalone quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 45 | 39 | 54 | 62 | |
| 39 | 35 | 45 | 52 | |
| Operating Profit | 6 | 4 | 8 | 10 |
| OPM % | 12.86% | 11.37% | 15.61% | 16.74% |
| 0 | 0 | 0 | 1 | |
| Interest | 1 | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 2 | 3 |
| Profit before Tax | 4 | 3 | 4 | 6 |
| Tax % | 11.66% | 27.57% | 19.05% | 23.53% |
| Net Profit | 3 | 2 | 4 | 5 |
| EPS | 2.84 | 1.56 | 2.73 | 2.73 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 11%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 14%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- -20%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 13%
- Last Year:
- 12%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 6 | 6 | 13 | 18 |
| 10 | 12 | 12 | 37 | |
| 13 | 30 | 27 | 11 | |
| Trade Payables | 4 | 7 | 14 | 17 |
| 4 | 4 | 8 | 8 | |
| Total Liabilities | 37 | 59 | 74 | 91 |
| 17 | 43 | 43 | 41 | |
| Capital Work in Progress | 4 | 0 | 0 | 0 |
| 3 | 6 | 9 | 16 | |
| 0 | 0 | 15 | 20 | |
| Cash & Bank | 0 | 0 | 1 | 9 |
| 13 | 10 | 5 | 5 | |
| Total Assets | 37 | 59 | 74 | 91 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0 | 6 | 2 | 1 | |
| Cash from Investing | -6 | -23 | -3 | 1 |
| Cash from Financing | 5 | 16 | 3 | 5 |
| -0 | -0 | 1 | 7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
No announcements filed.
News
Recent coverage and analyst commentary for ONYX
Loading news…
AI Stock Analyst
Onyx Biotec Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account